Spots Global Cancer Trial Database for talquetamab
Every month we try and update this database with for talquetamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | NCT06066346 | Multiple Myelom... | Talquetamab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | NCT06066346 | Multiple Myelom... | Talquetamab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | NCT03601078 | Multiple Myelom... | bb2121 Lenalomide Talquetamab | 18 Years - | Celgene | |
| A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | NCT04773522 | Multiple Myelom... | Talquetamab | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | NCT05503550 | Relapsed or Ref... | Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04586426 | Multiple Myelom... | Talquetamab Teclistamab Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | NCT05552222 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide Dexamethasone Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04586426 | Multiple Myelom... | Talquetamab Teclistamab Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | NCT06066346 | Multiple Myelom... | Talquetamab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | NCT05503550 | Relapsed or Ref... | Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT03399799 | Hematological M... | Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | NCT04773522 | Multiple Myelom... | Talquetamab | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | NCT05552222 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide Dexamethasone Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | NCT06348108 | Multiple Myelom... Refractory Mult... Relapsed Multip... | Talquetamab Iberdomide Dexamethasone Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | NCT06353022 | Multiple Myelom... | Teclistamab Talquetamab Lenalidomide Bortezomib Daratumumab Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | NCT05552222 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide Dexamethasone Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) | NCT06100237 | Multiple Myelom... | Teclistamab Talquetamab Daratumumab SC | 18 Years - | University of Miami | |
| Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | NCT05849610 | High-Risk de No... | Daratumumab Bortezomib Lenalidomide Teclistamab Talquetamab | 18 Years - | PETHEMA Foundation | |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | NCT06353022 | Multiple Myelom... | Teclistamab Talquetamab Lenalidomide Bortezomib Daratumumab Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma | NCT05757973 | Relapsed or Ref... | Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT05050097 | Multiple Myelom... | Talquetamab Carfilzomib Daratumumab SC Lenalidomide Pomalidomide | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04634552 | Hematological M... | Talquetamab | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
